This page contains a Flash digital edition of a book.
PRIME PEOPLE | JOAN CARLES FONT |


JOAN CARLES FONT MESOESTETIC


Balraj Juttla interviews Joan Carles Font, Group Founder and CEO of mesoestetic Pharma Group, about the company's long history in the aesthetic market and how it continues to grow in the future


How did you start the company? mesoestetic Pharma Group is a pharmaceutical laboratory of worldwide reference in the medical cosmetics sector that offers the most innovative and efficient solutions for skin treatment and care. Its origins date back to 1984 when, from my pharmacy in the centre of Barcelona, I started to develop my own cosmetics. Since its founding, the company has been committed to developing and marketing high quality products with scientifically-proven results and whose manufacturing and control processes are regulated by stringent pharmaceutical protocols. All our facilities have been approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) and comply with European Good Manufacturing Practice (GMP) regulations and guidelines. In addition, we have obtained the ISO 9001:2008 and ISO 13485:2003 quality management system certifications for all our activities.


80 ❚


What are the core values of the company? Passion for what we do. Passion to improve, excel, and innovate. This passion is the


key to who we are, and it is the key to who we are going to be. Our attitude is always a quest for


excellence. Everything can be improved. Everything is possible. This is the DNA of all the company’s staff. Our commitment to quality products


and services is our top priority and major motivation.


Why is it important for you to develop products in collaboration with hospitals? Because innovation is a benchmark in mesoestetic Pharma Group. Our growth is linked to our ongoing efforts in research and to our collaboration with hospitals, universities and renowned specialists in the sector who collaborate on researching into new treatments. As evidence of this strategic


commitment, 10 months ago we inaugurated a new biotechnology unit for performing cell culture assays to discover and develop more effective active ingredients. In addition, the unit will be used to establish contact with scientific groups and companies, and investigate active substances in depigmentation and


October 2013 | prime-journal.com


ageing, as well as growth factors and stem cells for dermatological and aesthetic purposes. With this new biotechnology unit and a


monitoring and follow-up unit, the company now handles the entire production cycle and can carry out in vitro and in vivo studies to ensure the safety and efficacy of our products.


How has the market changed since you started the company? The market has gone full circle. The cosmetics industry has now created a range of products equivalent to those found in the pharmaceutical sphere and these support the practice of medicine itself. This has been made possible by the European authorities' willingness to permit the manufacture of products such as technical fillers with therapeutic effects. Our image-driven society seeks to prevent the degenerative processes that are intrinsic to nature and life. At mesoestetic we strive to help delay what is irreversible. Today's new technologies provide everyone with more information, meaning that consumers are in a better position to choose products and their quality.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100